Indian pharmaceutical industry is poised on the curve of an exciting period of growth driven by growing prosperity and with large scale consolidation being the hallmark in this sector.

The Indian pharmaceutical market is expected to grow to US$ 55 billion by 2020 and further holds potential to reach US$ 70 billion at a CAGR of 17%.

India’s pharmaceutical industry constitutes of about 8% of the world’s pharmaceutical production and Indian pharma companies have been increasingly targeted by multinationals for both collaborative agreements and acquisitions.

The drugs and pharmaceuticals sector attracted foreign direct investments (FDI) worth US$ 4,89 billion between April 2000 and August 2011.

Indian Government decided to continue with 100% foreign direct investment (FDI) regime in the pharmaceuticals sector and there is going to be no cap in this industry.

The growth of the Indian pharmaceutical market is accompanied by endanger around the regulatory environment, disease trends, prescription specimen, research & development capability, healthcare spending and enablers like health insurance and distribution infrastructure.

The Indian companies have historically focused on generics with limited research capabilities and in order to meet international standards India’s Pharma sector will invest 25 billion USD in the coming 10 years in new technologies to keep with the pace of development in future markets.

The Department of Pharmaceuticals has prepared a "Pharma Vision 2020" for making India one of the leading destinations for end to end drug discovery and innovation.

This industry must enter into higher platforms of biotechnology, inventive drugs and fast track articulation of a new delivery model to achieve behemoth market presence.

It is essential to navigate forward in this sector and encompass how you decode business interpretation and how you mobilize your resources to contribute to healthy conclusions and vitality for this industry.